(mirdametinib)

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI (mirdametinib), Manufactured By SpringWorks Therapeutics

LOUISVILLE, Ky., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a…

4 weeks ago

UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on…

1 month ago

SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

– GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN – – Approval based on…

1 month ago